Automatic Estimation of the Apnea-hypopnea Index Using Neural Networks to Detect Sleep Apnea
NCT ID: NCT02143297
Last Updated: 2014-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
322 participants
OBSERVATIONAL
2013-07-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Severity Of Individual Breathing Cessation Events In Diagnostics Of Obstructive Sleep Apnea
NCT03232658
Evaluation Of Patients With Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) Based on Nonlinear Analysis Of Respiratory Signals
NCT01161381
Evaluation of the Cost-Effectiveness and Sensitivity of Automatic Analysis Versus Manual Analysis of Polygraphy in the Diagnosis of Obstructive Sleep Apnea.
NCT06458777
Sleep Apnea Syndrome and Community Acquired Pneumonia
NCT01071421
Daytime Sleepiness in Patients With the Assessment of a Sleep-related Respiratory Disorder
NCT04448470
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The standard apnea-hypopnea index (AHI) from PSG is used to diagnose SAHS. According to the American Academy of Sleep Medicine (AASM) rules, apnea is defined as a drop in the airflow signal greater than or equal to 90% from baseline lasting at least 10s, whereas hypopnea is defined as a drop greater than or equal to 50% during at least 10 s accompanied by a desaturation greater than or equal to 3% and/or an arousal. Subjects with an AHI \>= 10 events per hour (e/h) are diagnosed as suffering from SAHS.
A portable pulseoximeter (WristOX2 3150, Nonin) is used for ambulatory NPO. NPO is carried out the day immediately before or after the PSG at patient's home. Patients are assigned to carry out the NPO study before or after in-hospital PSG randomly. In addition, oximetry is also performed simultaneously to the PSG by means of the portable pulseoximeter. Therefore, every patient has 3 oximetric recordings: (i) SpO2 from unattended portable monitoring at home, (ii) SpO2 from attended in-hospital portable monitoring and (iii) SpO2 from attended in-hospital standard PSG.
SpO2 is recorded at a sampling rate of 1 Hz. All SpO2 recordings are saved to separate files and process offline. An automatic signal pre-processing stage is carried out to remove artifacts.
Our methodology is divided into two stages: feature extraction and pattern recognition. Oximetric recordings are parameterized by means of 16 features from four feature subsets to compose the initial feature set from oximetry: time domain statistics, frequency domain statistics, conventional spectral measures and nonlinear features. All features are computed for each whole overnight recording.
* Features 1 to 4. First to fourth-order moments (M1t - M4t) in the time domain: arithmetic mean (M1t), variance (M2t), skewness (M3t) and kurtosis (M4t) are applied to quantify central tendency, amount of dispersion, asymmetry and peakedness, respectively.
* Features 5 to 8. First to fourth-order moments (M1f - M4f) in the frequency domain.
* Feature 9. Median frequency (MF), which is defined as the component which comprises 50% of signal power.
* Feature 10. Spectral entropy (SE), which is a disorder quantifier related to the flatness of the spectrum.
* Feature 11. Total spectral power (PT), which is computed as the total area under the PSD.
* Feature 12. Peak amplitude (PA) in the apnea frequency band, which is the local maximum of the spectral content in the frequency range 0.014 - 0.033 Hz.
* Feature 13. Relative power (PR), which is the ratio of the area enclosed under the PSD in the apnea frequency band to the total signal power.
* Feature 14. Sample entropy (SampEn), which quantifies irregularity in time series, with larger values corresponding to more irregular data.
* Feature 15. Central tendency measure (CTM), which provides a variability measure from second order difference plots.
* Feature 16. Lempel - Ziv complexity (LZC), which is a measure of complexity linked with the rate of new subsequences and their repetition along the signal.
The second stage corresponds to regression analysis, which aims to provide an analytical expression for the AHI as a function of the extracted features. A multilayer perceptron (MLP) neural network is used. MLP networks are models for expressing knowledge using a connectionist paradigm inspired in the human brain. They are composed of multiple simple units or neurons known as perceptrons. Perceptrons are arranged in several interconnected layers. Each network connection between two of them is associated with a network adaptive parameter or weight. MLP networks with a single hidden layer composed of nonlinear perceptrons (i.e., with a nonlinear activation function) are implemented since they are capable of universal approximation. The proposed regression task aims to approximate a 1-D continuous variable representing the AHI. Thus, a single output unit with a linear activation function is required.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SAHS negative
Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally do not have the disease according to standard PSG
No interventions assigned to this group
SAHS positive
Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally have the disease according to standard PSG
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects submitted to the sleep unit due to previous symptoms of sleep apnea (daytime hypersomnolence, loud snoring, nocturnal choking and awakenings, and/or apnoeic events)
* Written informed consent signed
Exclusion Criteria
* Subjects not signing the informed consent
* Presence of any previously diagnosed sleep disorders: narcolepsy, insomnia, chronic sleep deprivation, regular use of hypnotic or sedative medications and restless leg syndrome
* Patients with chronic diseases: congestive heart failure, renal failure, neuromuscular diseases, chronic respiratory failure
* Patients with \> 50% of central apneas or the presence of Cheyne-Stokes respiration
* Previous CPAP treatment for SAHS diagnosis
* A medical history that may interfere with the study objectives or, in the opinion of the investigator, compromise the conclusions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sociedad Española de Neumología y Cirugía Torácica
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Félix del Campo
PhD, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Felix Del Campo, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Río Hortega, University of Valladolid
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Río Hortega
Valladolid, Valladolid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Biomedical Engineering Group (GIB) Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SEPAR-265/2012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.